# A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for

Source: https://onco.cc/trials/nct07728955/  
OnCo record `nct07728955` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of anlotinib and etoposide in lung cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, not yet recruiting.

## Summary

A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy is a phase 3, interventional study registered as NCT07728955 by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, with a registry enrolment figure of 64 participants, started 2026-08-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: benmelstobart in combination with anlotinib and etoposide. Conditions listed: Small Cell Lung Cancer ( SCLC ). Primary outcome: Progression-Free Survival (PFS). Lung eligibility wording from the registry: "Intensive treatment is defined as first-line intensive therapy for metastatic small cell lung cancer, i". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: SCLC
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07728955
- Phase: 3
- Setting: A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy
- Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Enrolled: 64

## Sources

- ClinicalTrials.gov NCT07728955: https://clinicaltrials.gov/study/NCT07728955

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/), [Etoposide](https://onco.cc/drugs/etoposide/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07728955.json